Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy

No abstract is available for this paper.

• Publication year

  1984

• Venue

  British Journal of Haematology

• Publication date

  1984-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2141.1984.tb06116.xPMID 6518137
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma.

  1983cited by this paper
• Kinetics of circulating B lymphocytes in human myeloma.

  1983cited by this paper
• Human myeloma: kinetics of the remission phase.

  1982cited by this paper
• Monoclonal gammopathy of undetermined significance (MGUS): a review.

  1982cited by this paper
• Identical twin marrow transplantation in multiple myeloma.

  1982cited by this paper
• Ploidy and proliferative characteristics in monoclonal gammopathies.

  1982cited by this paper
• Differentiation between benign and malignant monoclonal gammopathy by the presence of the J chain.

  1981cited by this paper
• Morphologic manifestations of monoclonal gammopathies.

  1981cited by this paper
• Reappraisal of plateau phase in myeloma.

  1980cited by this paper
• Smoldering multiple myeloma.

  1980cited by this paper
• Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma.

  1980cited by this paper
• [Plasma cell beta-glucuronidase and monoclonal gammapathies (author's transl)].

  1979cited by this paper
• Leukemic myelomatosis (plasma cell leukemia).

  1978cited by this paper
• Differentiation between benign and malignant monoclonal gammopathies by discriminant analysis on serum and bone marrow parameters.

  1978cited by this paper
• Unmaintained remissions in multiple myeloma.

  1978cited by this paper
• Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.

  1978cited by this paper
• Plasma cell acid phosphatase, a discriminative test for benign and malignant monoclonal gammopathies.

  1977cited by this paper
• A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

  1975cited by this paper
• High speed scintillation autoradiography

  1975cited by this paper
• Total body irradiation for myelomatosis.

  1971cited by this paper
• Drug Resistance in Multiple Myeloma Associated With High In Vitro Incorporation of 3 H-Thymidine

  year unknowncited by this paper

• RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma

  2023cites this paper
• Amino Acid and Proliferation PET/CT for the Diagnosis of Multiple Myeloma

  2022cites this paper
• Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.

  2020cites this paper
• Genomic Instability in Multiple Myeloma.

  2020cites this paper
• Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review).

  2016cites this paper
• CLINICAL-HEMATOLOGICAL FEATURES AND PROGNOSTIC SIGNIFICANT FACTORS IN PATIENTS WITH MULTIPLE MYELOMA

  2015cites this paper
• Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma

  2014cites this paper
• Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma

  2013cites this paper
• Gene Expression Profiling in Multiple Myeloma—Reporting of Entities, Risk, and Targets in Clinical Routine

  2011cites this paper
• The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.

  2011cites this paper
• Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

  2011cites this paper
• Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis.

  2011cites this paper
• cell-associated antigens as an indicator of poor survival Multiple myeloma: increased circulating lymphocytes carrying plasma

  2011cites this paper
• Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.

  2011cites this paper
• S- phase plasma cells A new staging system for multiple myeloma based on the number of

  2011cites this paper
• Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma.

  2010cites this paper
• Diagnostic value of the concentration of M-component in initial classification of monoclonal gammopathy.

  2009cites this paper
• Monitoring of plasma cell proliferative and apoptotic indices in the course of multiple myeloma

  2009cites this paper
• Benign monoclonal gammopathy presenting with severe renal failure.

  2009cites this paper
• AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

  2008cites this paper
• Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.

  2008cites this paper
• Time to first disease progression, but not β2‐microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy

  2007cites this paper
• New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals.

  2005cites this paper
• Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials.

  2004cites this paper
• Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

  2002cites this paper
• Severe and long‐lasting disruption of T‐cell receptor diversity in human myeloma after high‐dose chemotherapy and autologous peripheral blood progenitor cell infusion

  2001cites this paper
• A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death.

  2001cites this paper
• Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies.

  2000cites this paper
• Smoldering, asymptomatic stage 1, and indolent myeloma

  2000cites this paper
• Clinical features and outcome of multiple myeloma arising from the transformation of a monoclonal gammapathy of undetermined significance.

  1999cites this paper
• Clinical Features and Outcome of Multiple Myeloma Arising from the Transformation of a Monoclonal Gammapathy of Undertermined Significance

  1999cites this paper
• CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.

  1999cites this paper
• Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders

  1999cites this paper
• Prognostic significance of the S‐phase fraction of light‐chain‐restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on eastern cooperative oncology group treatment trial E9486

  1999cites this paper
• Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy.

  1999cites this paper
• Increased sialylation of oligosaccharides on IgG paraproteins--a potential new tumour marker in multiple myeloma.

  1998cites this paper
• Multiple myeloma.

  1997cites this paper
• Diagnosis, prognosis, and standard treatment of multiple myeloma.

  1997cites this paper
• Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein.

  1997cites this paper
• The significance of light chain-restricted bone marrow plasma cells after peripheral blood stem cell transplantation for multiple myeloma.

  1997cites this paper
• New insights in the clinical biology of multiple myeloma.

  1997cites this paper
• Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.

  1997cites this paper
• DISTRIBUTION OF T‐CELL SIGNALLING MOLECULES IN HUMAN MYELOMA

  1997cites this paper
• Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies.

  1996cites this paper
• A new staging system for multiple myeloma based on the number of S-phase plasma cells.

  1995cites this paper
• Retinoic acid inhibits the growth of human myeloma cells in vitro

  1995cites this paper
• A New Staging System for Multiple Myeloma Based on the Number of S-Phase Plasma Cells

  1995cites this paper
• Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis.

  1995cites this paper
• Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma.

  1995cites this paper
• Plasma cell proliferation in monoclonal gammopathy: relations with other biologic variables--diagnostic and prognostic significance.

  1995cites this paper
• 1Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis

  1995cites this paper
• PCNA immunopositivity index as a substitute to 3H-thymidine pulse-labeling index (TLI) in methanol-fixed human lymphocytes.

  1995cites this paper
• Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance.

  1995cites this paper
• Plasma cell proliferation in monoclonal gammopathies: measurement using BU-1 antibody in flow cytometry and microscopy: comparison with serum thymidine kinase.

  1995cites this paper
• Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma.

  1995cites this paper
• Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.

  1995cites this paper
• Mechanisms of the escape phase of myeloma.

  1994cites this paper
• Recombinant interferon‐γ inhibits the in vitro proliferation of human myeloma cells

  1994cites this paper
• Bone marrow angiogenesis and progression in multiple myeloma

  1994cites this paper
• Multiple myeloma.

  1994cites this paper
• AgNORs and myeloma prognosis.

  1994cites this paper
• Multiple myeloma: an overview of diagnosis and management.

  1994cites this paper
• Prognostic factors in myeloma: what they tell us about the pathophysiology of the disease.

  1994cites this paper
• MULTIPLE MYELOMA: WHY DOES THE DISEASE ESCAPE FROM PLATEAU PHASE?

  1994cites this paper
• Current Issues in Cancer: Multiple myeloma

  1994cites this paper
• Recombinant interferon-gamma inhibits the in vitro proliferation of human myeloma cells.

  1994cites this paper
• A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique.

  1994cites this paper
• Choice of fixation and denaturation for the triple labelling of intra-cytoplasmic antigen, bromodeoxyuridine and DNA

  1994cites this paper
• Multiple myeloma: expression of nucleoside transporters on malignant plasma cells and their relationship to cellular proliferation.

  1994cites this paper
• Risk of disease progression in asymptomatic multiple myeloma.

  1993cites this paper
• Multiple myeloma: ‘early’ plasma cell phenotype identifies patients with aggressive biological and clinical characteristics

  1993cites this paper
• [Human plasmacytoma from biology to clinical practice].

  1993cites this paper
• The biological and clinical significance of the KI‐67 growth fraction in multiple myeloma

  1992cites this paper
• Advances in the diagnosis and management of myeloma.

  1992cites this paper
• Serum levels of beta 2 microglobulin and interleukin-6 to differentiate monoclonal gammopathy of undetermined significance.

  1992cites this paper
• Assessment of Cell Proliferation in Clinical Practice

  1992cites this paper
• Clinical Aspects of Assessing Cell Proliferation

  1992cites this paper
• Multiple myeloma: prognostic factors and treatment modalities.

  1992cites this paper
• The value of the bone marrow plasma cell cytoplasmic light chain ratio in differentiating between multiple myeloma and monoclonal gammopathy of undetermined significance.

  1992cites this paper
• C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.

  1992cites this paper
• DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations

  1991cites this paper
• Prognosis and epidemiology of plasmocytomas

  1991cites this paper
• Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma

  1991cites this paper
• Monoclonal gammopathy as a model for B-cell differentiation: from "paraprotein" to artificial antibodies.

  1991cites this paper
• Determination of plasma cell labelling index with bromodeoxyuridine using a double immunoenzymatic technique.

  1990cites this paper
• Diagnostic and prognostic value of the MB2 monoclonal antibody in paraffin-embedded bone marrow sections of patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

  1990cites this paper
• Defective interleukin‐2 induction of lymphokine‐activatedkiller (LAK) activity in peripheral blood T lymphocytesof patients with monoclonal gammopathies

  1990cites this paper
• B‐cell surface phenotypes of proliferating myeloma cells: Target antigens for immunotherapy

  1990cites this paper
• Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.

  1990cites this paper
• Use of cytoplasmic 5'nucleotidase for differentiating malignant from benign monoclonal gammopathies.

  1990cites this paper
• Kappa/lambda ratio on peripheral blood lymphocytes and bone marrow plasma cell labeling index in monoclonal gammopathies.

  1990cites this paper
• Diagnostic and Prognostic Value of the MB2 Monoclonal Antibody in Paraffin-Em bedded Bone Marrow Sections of Patients with Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance

  1990cites this paper
• Hämatologische Neoplasien: Klinisch latent — aber behandlungsbedürftig?

  1990cites this paper
• Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival.

  1990cites this paper
• Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma.

  1989cites this paper
• Altered expression of growth-regulated protooncogenes in human malignant plasma cells.

  1989cites this paper
• Maintenance treatment of multiple myeloma

  1989cites this paper
• Dual parameter analysis of myeloma cells by flow cytometry. DNA content of cells containing monotypic cytoplasmic immunoglobulin.

  1989cites this paper
• Low circulating T‐helper cells in relapsing multiple myeloma

  1989cites this paper
• [New therapeutic approaches in multiple myeloma].

  1989cites this paper